Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...

MANILA, Philippines — The country’s total outstanding debt climbed to a fresh high of P16.68 trillion as of end-March, 12 percent higher than last year’s P14.93 trillion, the Bureau of the ...

in the January to March period by 9 percent to P16.6 billion, with the company already expecting to exceed its full-year earnings record. BPI president Jose Teodoro Limcaoco confirmed to reporters ...

State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer Doxorubicin plus trabectedin followed by trabectedin maintenance showed a survival advantage ...

Singapore will hold general elections on May 3, authorities in the city-state have said, paving the way for the first electoral test of Prime Minister Lawrence Wong since he entered office last year.

CDK4/6 inhibitor Verzenio (abemaciclib) was the third drug in the class to reach the market, first approved in 2017 as a second-line treatment for post-menopausal patients with hormone receptor ...

Among the new phase 3 starts are CDK4 inhibitor atirmociclib as a second-line therapy for hormone receptor-positive metastatic breast cancer, IB6-directed ADC sigvotatug vedotin for non-small cell ...

Dr. Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated GEP-NETs. They share the latest recommendations on managing symptoms ...

In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers.

Meihua Li and Apeng Liang contributed equally to this work. FDA approved CDK4/6 inhibition medicines has demonstrated significant clinical benefits in patients with HR+/HER2- breast cancer. However, ...